Biopharma M&A: deal-depressed third quarter leaves nowhere to hide

Biopharma M&A: deal-depressed third quarter leaves nowhere to hide

Submitted by admin on October 8, 2019 - 10:53am
Source: 
EP Vantage
News Tags: 
M&A
Lundbeck
Alder Biopharmaceuticals
Gilead Sciences
Galapagos
Vertex Pharmaceuticals
Semma
Swedish Orphan Biovitrum
Dova Pharmaceuticals
Novartis
IFM
Headline: 
Biopharma M&A: deal-depressed third quarter leaves nowhere to hide
snippet: 

Megadeals flattered the biopharma M&A scene in the first half of 2019, but the numbers took a nose dive in the third-quarter.

Do Not Allow Advertisers to Use My Personal information